Recent Progress in Understanding Pediatric Bipolar Disorder

Goldstein, Benjamin I.

doi:10.1001/archpediatrics.2011.832

Cited by 37 publications

(28 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the concepts of “over‐diagnosis” and “over‐treatment” in pediatric BD have received substantial attention,565 representative population studies demonstrate that adolescent BD is characterized by low rates of treatment, alongside high rates of suicidality and comorbidity 566, 567. Risks of incorrectly diagnosing and treating BD in a child or adolescent should thus be carefully weighed against the risk of incorrectly or not diagnosing or treating,568 keeping in mind that the duration of treatment delay has been shown to be an independent risk factor for a poor outcome in adulthood 569…”

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…BPB'nin yüksek oranda ailesel olduğu bilinmektedir (Goldstein 2012). BPB'si olan ebeveynlerin çocukları, hastalığın ortaya çıkması açısından yüksek risk grubu olarak kabul edilmektedir (Emiroğlu ve Diler 2009).…”

Section: Yüksek Risk Grubunda Epidemiyolojiunclassified

“…Son yıllarda, pediatrik BPB tanısının konulamaması ve düşük yaygınlık tahminlerine ilişkin endişelerin yerini, yanlış BPB tanılaması ve tahmin üstü yaygınlık oranı ile ilişkili endişeler almıştır (Goldstein 2012). 1990'ların ortalarından itibaren oluşan kavramsal değişiklikler, özellikle Amerika'da BPB tanılarının artmasına yol açmıştır (Parry ve Levin 2012).…”

Section: Wwwcappsyorgunclassified

See 1 more Smart Citation

Epidemiology in Pediatric Bipolar Disorder

Mutlu¹,

Doksat²,

Erdoğan³

2015

Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychia

View full text Add to dashboard Cite

ÖzetÇocuk ve ergenlerde bipolar bozukluk tanısı giderek artış göstermektedir. Çocuk ve ergen popülas-yonunda intihar girişiminde bulunanların önemli bir oranının bipolar bozukluğu olanlarda ortaya çıkıyor olması, bu hastalığın tanı ve tedavisini daha da önemli kılmaktadır. Özellikle ergenlik dönemi öncesi örneklemlerde açık tanı ölçütlerinin olmaması ve değerlendirmelerin belirtilere dayanılarak yapılmasından dolayı yanlış biçimde bipolar bozukluk tanısı konduğu ve yaygınlık oranlarının olduğundan fazla saptandığına dair endişeler vardır. Bunlardan ötürü, çocuk ve ergen bipolar bozukluğunun yaygınlığı konusundaki veriler hem farklılık göstermekte hem de tartışılmaktadır. Bu derleme çalışmasında, bipolar bozukluğun yaygınlığı toplum, poliklinik ve yatan hasta örneklemin-de literatür gözden geçirilmiştir. AbstractChildhood and adolescent bipolar disorder diagnosis has been increasing recently. Since studies evaluating attempted suicide rates in children and adolescents have shown bipolarity to be a significant risk factor, diagnosis and treatment of bipolarity has become a very important issue. Since there is a lack of specific diagnostic criteria for especially preadolescent samples and evaluations are made mostly symptomatically, suspicions about false true diagnosis and increased prevalence rates have emerged. This situation leads to controversial data about the prevalence rates of bipolar disorder in children and adolescents. The aim of this article is to review the prevalence of childhood and adolescent bipolar disorder in community, inpatient and outpatient based samples in literature.

show abstract

“…Methods for precise diagnosis and treatment for their diseases are developing, but not have been adequately established yet. For example, bipolar disorder is a chronic disease whose onset occurs in adolescence, but is often misdiagnosed [1]. Finding biomarkers, such as Brain-Derived Neurotrophic Factor (BDNF) for major depressive disorders [2], and utilizing them to diagnose patients rapidly, and give them a tailor-made treatment are desired.…”

mentioning

confidence: 99%

Current Issues around Child and Adolescent Behaviors

Shiina¹

2013

J Child Adolesc Behav

View full text Add to dashboard Cite

Recent Progress in Understanding Pediatric Bipolar Disorder

Cited by 37 publications

References 100 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Epidemiology in Pediatric Bipolar Disorder

Current Issues around Child and Adolescent Behaviors

Contact Info

Product

Resources

About